Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study
Open Access
- 23 October 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11), 3406
- https://doi.org/10.3390/jcm9113406
Abstract
Inhaled corticosteroids (ICS) could increase both the risk of coronavirus disease 2019 (COVID-19) and experiencing poor outcomes. To compare the clinical outcomes between ICS users and nonusers, COVID-19-related claims in the Korean Health Insurance Review and Assessment database were evaluated. To evaluate susceptibility to COVID-19 among patients with COPD or asthma, a nested case-control study was performed using the same database. In total, 7341 patients were confirmed to have COVID-19, including 114 ICS users and 7227 nonusers. Among 5910 patients who were hospitalized, death was observed for 9% of ICS users and 4% of nonusers. However, this association was not significant when adjusted for age, sex, region, comorbidities, and hospital type (aOR, 0.94; 95% CI, 0.43–2.07). The case-control analysis of COPD compared 640 cases with COVID-19 to 2560 matched controls without COVID-19, and the analysis of asthma compared 90 cases with COVID-19 to 360 matched controls without COVID-19. Use of ICS was not significantly associated with COVID-19 among patients with COPD (aOR, 1.02; 95% CI, 0.46–2.25) or asthma (aOR, 0.38; 95% CI, 0.13–1.17). Prior ICS use was not significantly associated with COVID-19 in patients with COPD or asthma, nor with clinical outcomes among patients with COVID-19.This publication has 31 references indexed in Scilit:
- Inhaled Corticosteroids and the Risk of Pneumonia in People With AsthmaSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2013
- Inhaled corticosteroids for stable chronic obstructive pulmonary diseaseEmergencias, 2012
- Prevalence of chronic obstructive pulmonary disease in Korea: The fourth Korean National Health and Nutrition Examination Survey, 2008Respirology, 2011
- Respiratory viruses and eosinophils: Exploring the connectionsAntiviral Research, 2009
- Global strategy for asthma management and prevention: GINA executive summaryEuropean Respiratory Journal, 2008
- SARS: Systematic Review of Treatment EffectsPLoS Medicine, 2006
- Role of deficient type III interferon-λ production in asthma exacerbationsNature Medicine, 2006
- The global burden of asthma: executive summary of the GINA Dissemination Committee ReportAllergy, 2004
- IL-9 Inhibits Oxidative Burst and TNF-α Release in Lipopolysaccharide-Stimulated Human Monocytes Through TGF-βThe Journal of Immunology, 2002
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987